Ann: Trading Halt, page-20

'Sorry to spoil the weekend but that is what history tells.'

Sorry to spoil your skewed analogy, but the history for OBJ until now has shown little revenue....and we are now due for our first Quarterly that could most likely change that scenario.

These two pivotal announcements (4C and 'Licensing of a second Technology) are being set-up perfectly for a dream run into the coming Roadshows.

Let's go back to the BOD's Milestones due for expiry 28/11/2017:

Milestone 1 – Receipt by the Company of the first royalty payment resulting from a licence to a third party of the Company’s powered Dermaportation technology.

Milestone 2 – Execution of a new licence agreement with a third party for the utilisation of the Company’s ETP technology in a category other than skincare, beauty or grooming

Milestone 3 – Receipt by the Company of licencing fees in excess of $20,000,0000.



If I were to make a guess, it is not a single product like Gillette for example. More likely Dermaportation or DCE that can be applied to multiple products/brands/work plans. We already know it is P&G as evidenced below:


http://www.asx.com.au/asxpdf/20170130/pdf/43fl8bkt0b7tz0.pdf


http://www.asx.com.au/asxpdf/20170227/pdf/43gcfsns12kd81.pdf


BOD Milestones and process of elimination leads me to Dermaportation (with DCE a milder possibility).